NEWS ER
Monogram Technologies Reports Second Quarter 2024 Financial Results
Monogram Technologies (NASDAQ:MGRM) reported its Q2 2024 financial results, highlighting key operational achievements.
The company submitted a 510(k) premarket filing to the FDA for its mBôs TKA System, which passed the administrative review.
Monogram also secured a strategic collaboration with Shalby for multicenter clinical trials in India.
Financial results showed R&D expenses decreased to $2.4 million from $3.0 million year-over-year, while marketing expenses significantly dropped to $92,000 from $1.7 million.
The net loss improved to $3.5 million compared to $5.2 million in the prior-year quarter.
Cash and cash equivalents stood at $7.3 million as of June 30, 2024.
免责声明：社区由Moomoo Technologies Inc.提供，仅用于教育目的。
更多信息
评论
登录发表评论
